Education

What Is Retatrutide?

REPRIME Research·08 Feb 2026·5 min read·Updated 19 Aug 2026

What retatrutide (LY3437943) is, how its GIP + GLP-1 + glucagon triple-agonist design works, what clinical trials report, and how research-grade material is verified.

Retatrutide is an investigational synthetic peptide engineered to activate three metabolic receptors with a single molecule: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. It was developed at Eli Lilly under the code LY3437943 and is in late-stage clinical trials; it is not an approved medicine anywhere at the time of writing (August 2026). This guide explains what the molecule is, why the triple-agonist design matters, what the clinical literature reports, and what to check before working with research-grade material.

Retatrutide at a glance

Type: synthetic peptide, incretin family
Development code: LY3437943 (Eli Lilly)
Receptor targets: GIP, GLP-1, and glucagon receptors — a "triple agonist"
Status: investigational; phase 3 trials reported topline results through 2025–2026; no marketing approval as of August 2026
Form at REPRIME: lyophilized powder, batch-tested, with a published COA

What is retatrutide?

Retatrutide is a single engineered peptide with agonist activity at three receptors that regulate metabolism. Structurally, it is built on a backbone derived from GIP (glucose-dependent insulinotropic polypeptide), carries several non-natural amino-acid substitutions, and is acylated with a C20 fatty-diacid chain. That fatty-diacid modification lets the peptide bind serum albumin, which slows clearance enough to support once-weekly administration in clinical trials — the same engineering strategy used for tirzepatide before it (Coskun et al., 2022; see References).

The three receptors, briefly

GLP-1 receptor — the receptor for glucagon-like peptide-1, an incretin hormone released after meals. Single-agonist compounds in this class are the reference point for modern metabolic-pathway research.
GIP receptor — the receptor for glucose-dependent insulinotropic polypeptide, the other incretin. Engaging GIP and GLP-1 together is what defines dual agonists such as tirzepatide.
Glucagon receptor — glucagon signaling is associated in the literature with hepatic glucose handling and energy expenditure. This is the receptor retatrutide adds on top of the dual design.

How a triple agonist differs from single- and dual-agonist designs

Where earlier research peptides targeted single receptors, retatrutide's triple-agonist profile invites different experimental designs. One compound perturbs three signaling axes at once, so researchers can probe overlapping cascades without co-administering multiple compounds — the readout reflects the integrated state rather than three separate experiments stitched together.

The trade-off is attribution. When one molecule engages three receptors, separating which receptor drove which downstream effect requires selective single-agonist comparators in the protocol design. Whether that trade is worth it depends on the question being asked; the tirzepatide vs retatrutide comparison walks through the decision in detail.

What retatrutide is being studied for

The published record on the investigational medicine — reported here as literature facts, not as claims about research material or any use of it:

A 48-week phase 2 obesity trial reported a mean body-weight reduction of 24.2% at the highest dose studied (Jastreboff et al., NEJM, 2023).
A 36-week phase 2 trial in type 2 diabetes reported dose-dependent reductions in HbA1c and body weight (Rosenstock et al., The Lancet, 2023).
A phase 2a trial in metabolic dysfunction-associated steatotic liver disease (MASLD) reported reductions in liver-fat content (Nature Medicine, 2024).
The phase 3 TRIUMPH program reported positive topline results across 2025–2026, and the first phase 3 publication (TRANSCEND-T2D-1, in type 2 diabetes) appeared in The Lancet in 2026.

As of August 2026, retatrutide has no marketing approval in any jurisdiction. REPRIME supplies research-grade material for laboratory use only; nothing above is a claim about clinical use, and REPRIME provides no dosage or protocol guidance.

Terminology worth knowing

Incretin — a gut hormone released after nutrient intake that amplifies insulin secretion; GLP-1 and GIP are the two incretins.
Receptor agonist — a molecule that binds a receptor and activates it, as the natural ligand would.
Acylation — attaching a fatty-acid chain to a peptide so it binds albumin in serum, extending its half-life.
Lyophilization — freeze-drying into a stable powder; the reason research peptides ship dry. See Lyophilized Powder vs Solution.

Working with research-grade retatrutide

A research peptide is only as useful as its identity and purity. For every retatrutide batch, REPRIME publishes mass-spectrometry identity confirmation and an HPLC purity report in the open Certificates repository — Understanding Mass Spectrometry and Understanding HPLC Testing explain how to read both, and Reading a Certificate of Analysis walks the full document line by line.

Store the lyophilized vial at -20°C per Peptide Storage Guidelines, and scan the package code at /verify on first use — Chain of Custody and Product Authentication explains what that scan proves. The current batch, price, and COA are on the Retatrutide product page.

Frequently asked questions

Is retatrutide an approved medicine?

No. As of August 2026, retatrutide is investigational: its phase 3 trials have reported topline results, but it has no marketing approval in any jurisdiction. It is available only as a research compound or within clinical trials.

How is retatrutide different from tirzepatide?

Tirzepatide activates two receptors (GIP and GLP-1); retatrutide activates those two plus the glucagon receptor. Tirzepatide is an approved medicine in many jurisdictions, while retatrutide remains investigational. The full side-by-side comparison covers design, evidence, and research use.

What does "triple agonist" mean?

A triple agonist is a single molecule that binds and activates three different receptors. In retatrutide's case those are the GIP, GLP-1, and glucagon receptors, which is why the literature also calls it a GGG or triple-hormone-receptor agonist.

How do I confirm a retatrutide vial is genuine?

Check the batch COA in the Certificates repository and scan the unique code on the package insert at /verify. The first scan stamps the code as verified; a code that reports "already verified" on your first scan is the counterfeit warning signal.